We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
-7.05%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.34B
AUM Growth
+$132M
Cap. Flow
+$289M
Cap. Flow %
21.59%
Top 10 Hldgs %
54.87%
Holding
79
New
21
Increased
28
Reduced
5
Closed
19

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$72.2M
2
EXAS
Exact Sciences
EXAS
+$45.4M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$44M
4
JANX icon
Janux Therapeutics
JANX
+$34M
5
ACLX
Arcellx
ACLX
+$31.3M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$97.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$52.3M
3
AZN icon
AstraZeneca
AZN
+$27.1M
4
NARI
Inari Medical, Inc. Common Stock
NARI
+$19.9M
5
ARGX icon
argenx
ARGX
+$19.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
51
DELISTED
Ventyx Biosciences
VTYX
$3.04M 0.23%
+1,315,000
New +$5.46M
PTCT icon
52
PTC Therapeutics
PTCT
$5.78B
$2.75M 0.21%
+90,000
New +$2.92M
VERV
53
DELISTED
Verve Therapeutics
VERV
$2.44M 0.18%
+500,000
New +$3.14M
IOVA icon
54
Iovance Biotherapeutics
IOVA
$1.94B
$2.41M 0.18%
+300,000
New +$3.21M
PRME icon
55
Prime Medicine
PRME
$556M
$2.31M 0.17%
450,000
+90,000
+25% +$546K
CMRX
56
DELISTED
Chimerix, Inc.
CMRX
$1.23M 0.09%
1,400,000
– –
ACHL
57
DELISTED
Achilles Therapeutics
ACHL
$1.22M 0.09%
1,500,000
– –
ATRA icon
58
Atara Biotherapeutics
ATRA
$76.9M
$952K 0.07%
112,000
– –
OKUR
59
OnKure Therapeutics
OKUR
$168M
$823K 0.06%
54,500
+24,962
+85% +$423K
NAMS icon
60
NewAmsterdam Pharma
NAMS
$3.21B
$480K 0.04%
+25,000
New +$502K
AFMD
61
DELISTED
Affimed
AFMD
– –
-55,000
Closed -$292K
AGIO icon
62
Agios Pharmaceuticals
AGIO
$1.89B
– –
-325,000
Closed -$9.5M
ALNY icon
63
Alnylam Pharmaceuticals
ALNY
$30.6B
– –
-350,000
Closed -$52.3M
ARGX icon
64
argenx
ARGX
$54.3B
– –
-50,000
Closed -$19.7M
AZN icon
65
AstraZeneca
AZN
$250B
– –
-200,000
Closed -$27.1M
BIO icon
66
Bio-Rad Laboratories Class A
BIO
$9.31B
– –
-15,000
Closed -$5.19M
BMRN icon
67
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-175,000
Closed -$15.3M
GERN icon
68
Geron
GERN
$1.05B
– –
-2,200,000
Closed -$7.26M
INCY icon
69
Incyte
INCY
$24.3B
– –
-200,000
Closed -$11.4M
KRYS icon
70
Krystal Biotech
KRYS
$9.64B
– –
-45,000
Closed -$8.01M
LYEL icon
71
Lyell Immunopharma
LYEL
$330M
– –
-6,500
Closed -$290K
LYRA
72
DELISTED
LYRA THERAPEUTICS INC
LYRA
– –
-16,000
Closed -$4.98M
NBIX icon
73
Neurocrine Biosciences
NBIX
$16.4B
– –
-710,000
Closed -$97.9M
NVAX icon
74
Novavax
NVAX
$1.27B
– –
-500,000
Closed -$2.39M
SRPT icon
75
Sarepta Therapeutics
SRPT
$1.68B
– –
-100,000
Closed -$12.9M
1 2
3
4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Vestal Point Capital held 79 positions worth $1.34B, up 11% from $1.21B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Vestal Point Capital deployed $289M of net new capital in Q2 2024, opening 21 new positions and adding to 28 existing holdings. Its largest new stake was Janux Therapeutics: 725,000 shares worth $30.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Inari Medical, Inc. Common Stock, an estimated $19.9M trimmed.

  • Vestal Point Capital's largest Q2 2024 buy was Janux Therapeutics: 725,000 shares worth $30.4M.
  • Vestal Point Capital added most to Ultragenyx Pharmaceutical in Q2 2024, an estimated $72.2M increase.
  • Vestal Point Capital's biggest Q2 2024 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $19.9M.
  • Vestal Point Capital fully exited Neurocrine Biosciences in Q2 2024, selling an estimated $97.9M.
  • Vestal Point Capital's ten largest holdings make up 55% of its $1.34B portfolio in Q2 2024.
  • Vestal Point Capital opened 21 new positions and closed 19 in Q2 2024.
  • Vestal Point Capital's portfolio value rose 11% quarter-over-quarter to $1.34B.

Based on Vestal Point Capital's 13F filing for Q2 2024, filed 14 Aug 2024.